SI-BONE, Inc. (NASDAQ:SIBN - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for SI-BONE in a report released on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($0.64) per share for the year, down from their prior estimate of ($0.19). Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for SI-BONE's current full-year earnings is ($0.78) per share.
Several other equities research analysts also recently issued reports on SIBN. Truist Financial reaffirmed a "buy" rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC raised their target price on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $24.50.
Get Our Latest Analysis on SIBN
SI-BONE Stock Performance
SIBN traded down $0.55 during trading on Thursday, hitting $17.57. The stock had a trading volume of 306,542 shares, compared to its average volume of 358,124. The firm has a market cap of $745.90 million, a PE ratio of -19.10 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a 50 day simple moving average of $16.11 and a 200-day simple moving average of $14.81.
SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million.
Insider Activity
In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares of the company's stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the sale, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. The trade was a 1.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 9,311 shares of company stock valued at $130,356. Insiders own 3.90% of the company's stock.
Institutional Investors Weigh In On SI-BONE
Institutional investors and hedge funds have recently bought and sold shares of the business. Harbor Capital Advisors Inc. boosted its position in shares of SI-BONE by 222.5% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company's stock valued at $8,674,000 after acquiring an additional 428,110 shares in the last quarter. Impax Asset Management Group plc boosted its holdings in SI-BONE by 41.3% during the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after purchasing an additional 221,604 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of SI-BONE by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company's stock valued at $4,405,000 after purchasing an additional 5,966 shares during the period. Champlain Investment Partners LLC raised its holdings in shares of SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock worth $39,145,000 after buying an additional 358,821 shares in the last quarter. Finally, Millrace Asset Group Inc. bought a new position in shares of SI-BONE during the 3rd quarter worth approximately $1,056,000. Institutional investors own 98.11% of the company's stock.
About SI-BONE
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Recommended Stories
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
